CS1:LSE:LSE-Amundi IBEX 35 UCITS ETF Acc GBP (GBX)

ETF | Others |

Last Closing

USD 28467.5

Change

+5.00 (+0.02)%

Market Cap

USD 0.11B

Volume

394.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.08 (-0.53%)

USD 640.06B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.13 (-0.70%)

USD 640.06B
0R1I:LSE NVIDIA Corp.

+1.13 (+0.99%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
PRJU:LSE Amundi Index Solutions - Amund..

-0.24 (-0.76%)

USD 269.13B
0QZK:LSE Coca-Cola Co.

-0.50 (-0.69%)

USD 266.08B
0QZO:LSE 0QZO

+8.10 (+8.77%)

USD 258.54B
0QZ3:LSE Qualcomm Inc.

+2.10 (+1.51%)

USD 202.26B
0R24:LSE Intel Corp.

-0.66 (-3.19%)

USD 196.14B

ETFs Containing CS1:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.13% 96% N/A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.13% 95% A 90% A-
Trailing 12 Months  
Capital Gain 24.41% 94% A 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.41% 93% A 87% B+
Trailing 5 Years  
Capital Gain 130.88% 93% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 130.88% 91% A- 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 14.11% 80% B- 79% B-
Dividend Return 14.11% 79% B- 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.83% 56% F 74% C
Risk Adjusted Return 119.27% 97% N/A 98% N/A
Market Capitalization 0.11B 51% F 29% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike